Anecortave acetate for fibrotic lesions with presence of residual peripheral activity in age-related macular degeneration.

Abstract	We retrospectively examined the efficacy of a single juxtascleral anecortave acetate depot injection for the treatment of fibrotic choroidal neovascular lesions with presence of residual peripheral activity in age related macular degeneration in 20 consecutive patients who rejected intravitreal treatment. As a second line-therapy of classic and occult fibrotic lesions with active peripheral zones, anecortave seems to be a vision conserving therapeutic option.
Authors	Tina Aggermann, Paulina Haas, Susanne Binder
Journal	Annals of ophthalmology (Skokie, Ill.) (Ann Ophthalmol (Skokie)) Vol. 40 Issue 1 Pg. 28-30 ( 2008) ISSN: 1530-4086 [Print] United States
PMID	18556978 (Publication Type: Journal Article)
Chemical References	Angiogenesis Inhibitors Pregnadienediols anecortave acetate
Topics	Aged Aged, 80 and over Angiogenesis Inhibitors (therapeutic use) Choroidal Neovascularization (drug therapy) Female Fibrosis Humans Injections Macular Degeneration (drug therapy) Male Pregnadienediols (therapeutic use) Retrospective Studies Tomography, Optical Coherence Treatment Outcome Visual Acuity

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!